NCT06305143View on ClinicalTrials.gov

Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

July 1, 2025

Conditions
Diabetic Macular Edema
Interventions
DRUG

Conbercept

participants with diabetic macular edema (DME) combined with severe non-proliferative diabetes retinopathy (sNPDR) were assigned to anti-VEGF therapy over 12 months.

Trial Locations (1)

201103

Shanghai Eye Diseases Prevention &Treatment Center, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Shanghai Eye Disease Prevention and Treatment Center

OTHER

NCT06305143 - Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter